AI assistant
Processa Pharmaceuticals, Inc. — Director's Dealing 2024
Aug 2, 2024
35172_dirs_2024-08-02_0406478b-c36d-4df8-9abb-2bbd8e770ac6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2024-04-05
Reporting Person: Stanker James H (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-05 | Common Stock | M | 1675 | — | Acquired | 6638 | Direct |
| 2024-04-05 | Common Stock | F | 518 | $2.79 | Disposed | 6120 | Direct |
| 2024-07-10 | Common Stock | M | 644 | — | Acquired | 6764 | Direct |
| 2024-07-10 | Common Stock | F | 282 | $1.71 | Disposed | 6482 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-28 | Restricted Stock Units | $0 | A | 3077 | Acquired | Common Stock (3077) | Direct | |
| 2024-06-28 | Restricted Stock Units | $0 | A | 2307 | Acquired | Common Stock (2307) | Direct | |
| 2024-06-28 | Restricted Stock Units | $0 | A | 385 | Acquired | Common Stock (385) | Direct | |
| 2024-06-28 | Restricted Stock Units | $0 | A | 385 | Acquired | Common Stock (385) | Direct |
Footnotes
F1: Distribution of vested restricted shares.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.